Fc-based half-life extension of human FVIIa - a new player for hemophilia treatment?

被引：0
|
作者：
Margaritis, Paris [1 ]
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
来源：
THROMBOSIS RESEARCH | 2015年 / 135卷 / 05期
关键词：
Hemophilia; Coagulation Factor VIIa; Half-life; Fc fusion; RECOMBINANT FACTOR VIIA; COAGULATION-FACTOR VIIA; ALBUMIN RVIIA-FP; PROPHYLAXIS; INHIBITORS; EFFICACY;
D O I：
10.1016/j.thromres.2015.02.030
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：775 / 776
页数：2
相关论文
共 50 条
  • [41] HALF-LIFE OF HUMAN PTH INVIVO - PEROPERATIVE STUDY IN THE TREATMENT OF PARATHYROID ADENOMAS
    WERYHA, G
    KAMINSKY, P
    DETALANCE, N
    SCHJOT, B
    DUQUENNE, M
    MATHIEU, P
    LECLERE, J
    REVUE DE MEDECINE INTERNE, 1992, 13 : S360 - S360
  • [42] Changes in Quality of Life, Adherence, and Kinesiophobia in Patients with Hemophilia Treated with Extended Half-Life Treatment: Final Results of the LongHest Project
    Ucero-Lozano, Roberto
    Perez-Llanes, Raul
    Cuesta-Barriuso, Ruben
    Donoso-Ubeda, Elena
    PHARMACEUTICALS, 2024, 17 (07)
  • [43] EXTENDED HALF-LIFE FACTOR IX TREATMENT IN HEMOPHILIA B PATIENTS: PRELIMINARY DATA FROM A REFERENCE CENTER
    Benitez Hidalgo, O.
    Martinez Garcia, M. F.
    Juarez Gimenez, J. C.
    HAEMOPHILIA, 2021, 27 : 78 - 79
  • [44] Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Hemophilia a Patients
    Xue, Feng
    Sun, Jing
    Chen, Yun
    Zhang, Xinsheng
    Sun, Haiyan
    Wang, Yali
    Yang, Renchi
    BLOOD, 2019, 134
  • [45] Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice
    Sarafanov, Andrey G.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (10)
  • [46] TAWAM HOSPITAL, AL AIN, UAE EXPERIENCE WITH SWITCHING FROM STANDARD HALF-LIFE RECOMBINANT COAGULATION FACTOR IX TO EXTEND HALF-LIFE RECOMBINANT COAGULATION FACTOR IX, FC FUSION PROTEIN IN PATIENTS WITH SEVERE HEMOPHILIA B
    Khanani, M. F.
    Osman, H.
    Rayyan, M. Z.
    Al Habaybia, K.
    Alreyami, L. A. E. M.
    Abd El Fattah, M.
    HAEMOPHILIA, 2023, 29 : 86 - 87
  • [47] Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates
    Shen, Yijun
    Li, Hua
    Zhao, Li
    Li, Gang
    Chen, Ben
    Guo, Qingsong
    Gao, Bei
    Wu, Jinsong
    Yang, Tong
    Jin, Li
    Su, Yong
    PLOS ONE, 2017, 12 (08):
  • [48] Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria
    Foss, Stian
    Sakya, Siri A.
    Aguinagalde, Leire
    Lustig, Marta
    Shaughnessy, Jutamas
    Cruz, Ana Rita
    Scheepmaker, Lisette
    Mathiesen, Line
    Ruso-Julve, Fulgencio
    Anthi, Aina Karen
    Gjolberg, Torleif Tollefsrud
    Mester, Simone
    Bern, Malin
    Evers, Mitchell
    Bratlie, Diane B.
    Michaelsen, Terje E.
    Schlothauer, Tilman
    Sok, Devin
    Bhattacharya, Jayanta
    Leusen, Jeanette
    Valerius, Thomas
    Ram, Sanjay
    Rooijakkers, Suzan H. M.
    Sandlie, Inger
    Andersen, Jan Terje
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [49] Fc-fusion technology beyond half-life extension-Review of potential immunomodulatory and anti-inflammatory effects of rFVIIIFc in haemophilia A
    Lacroix-Desmazes, Sebastien
    Horneff, Regina
    Casiano, Sandra
    Santagostino, Elena
    HAEMOPHILIA, 2022, 28 : 30 - 31
  • [50] Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement
    Larsen, Maja Thim
    Rawsthorne, Helen
    Schelde, Karen Kraemmer
    Dagnaes-Hansen, Frederik
    Cameron, Jason
    Howard, Kenneth A.
    JOURNAL OF CONTROLLED RELEASE, 2018, 287 : 132 - 141
12345